Many of our leaders have worked together for more than 210 dog years, at some of the world’s largest pharmaceutical companies.
During those years we learned some important lessons the hard way. Like how important it is to match new products with true needs in the marketplace. And that making large investments before early stage clinical evaluation is a sure-fire way to end up in the doghouse.*
Today we know how to keep the process, and products, moving at the speed of a hyped-up puppy.
Our team has developed, launched, or marketed more than 15 companion animal products in the veterinary industry for dogs, cats, and horses.
Many of these products—like SENTINEL® (milbemycin oxime/lufenuron), and PERCORTEN-V® (DOCP), and CLARO® (florfenicol, terbinafine, mometasone furoate)—became or are becoming category top-sellers.
You’ll purr when you see the list of key milestones in the veterinary industry we’ve been a part of. We have more firsts than a cat has lives. To learn more click here.
If you want a proven track record, we have it in spades.
SENTINEL is a registered trademark of Virbac.
PERCORTEN-V is a registered trademark of Elanco.
CLARO is a registered trademark of Bayer HealthCare AG
It’s not enough to rest on laurels. That’s why we have been issued 46 patents, and have an additional 60 pending worldwide. In fact, we’ve introduced innovations across almost the entire spectrum of companion animal medicine—and touched nearly every product and treatment category.
Our entire team is constantly evaluating the marketplace for opportunities to fulfill unmet needs, even ones that pet owners and veterinarians don’t realize they have.
We’re currently focusing on veterinarian-administered single-treatment products--such as CLARO® (florfenicol, terbinafine, mometasone furoate) Otic Suspension for the treatment of otitis externa in dogs--that help ensure improved health for pets, while reducing pet-owner compliance concerns.
Easy treatments. Healthy pets. Hero veterinarians. Happy owners. It’s a formula that works.
Understanding why people love their companion animals is easy. Getting new or improved FDA-pharmaceuticals to market is not.
At Piedmont Animal Health we know a thing or two about streamlining the process, so nobody is stuck chasing their tail. In fact, we’ve been known to get products to market nearly 40% faster than the average time.*
Using human resource efficiencies—and hiring only the best team members—means we can remain an incredibly sleek organization, helping us stay flexible, so we can quickly adjust to changing market trends.
Piedmont Animal Health currently has more than 20 products in various stages of development, and have received approval on four new products from FDA since 2014. For example, in 2015, we received approval on two new animal drug applications (NADAs) from FDA’s Center for Veterinary Medicine, which accounted for 40% of all NADA approvals issued by FDA-CVM in that year.
We plan to commercialize more than 10 of the products in our current portfolio, and hold out-licensing agreements with major global pharmaceutical companies for the others.
Based on independent market research*, sales of our retained portfolio products are projected to reach $125 million annually.